Standard BioTools (LAB) Set to Announce Earnings on Monday

Standard BioTools (NASDAQ:LABGet Rating) will issue its quarterly earnings data after the market closes on Monday, August 8th. Parties that wish to listen to the company’s conference call can do so using this link.

Standard BioTools (NASDAQ:LABGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.31) earnings per share for the quarter. Standard BioTools had a negative return on equity of 63.43% and a negative net margin of 93.89%. The company had revenue of $26.50 million for the quarter.

Standard BioTools Price Performance

Shares of NASDAQ LAB opened at $1.89 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.06 and a debt-to-equity ratio of 4.52. The business’s fifty day moving average is $1.71. Standard BioTools has a 1-year low of $1.28 and a 1-year high of $7.31. The firm has a market capitalization of $146.01 million, a P/E ratio of -1.24 and a beta of 1.20.

Insider Buying and Selling

In other Standard BioTools news, major shareholder Caligan Partners Lp bought 100,000 shares of Standard BioTools stock in a transaction on Monday, June 13th. The stock was bought at an average price of $1.70 per share, with a total value of $170,000.00. Following the completion of the acquisition, the insider now owns 10,523,188 shares in the company, valued at $17,889,419.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders purchased a total of 693,857 shares of company stock valued at $1,140,612 over the last three months. 2.90% of the stock is currently owned by company insiders.

Standard BioTools Company Profile

(Get Rating)

Standard BioTools Inc creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology.

Featured Articles

Earnings History for Standard BioTools (NASDAQ:LAB)

Want More Great Investing Ideas?

Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with's FREE daily email newsletter.